Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis

RECOMMENDED

Pulmonary Fibrosis

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A

doi: 10.1016/S2213-2600(24)00411-9

RECOMMENDED

Pulmonary Fibrosis

BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Med

Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T

doi: 10.1016/j.rmed.2025.108080

Pulmonary Fibrosis

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

J Cyst Fibros

Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB

doi: 10.1016/j.jcf.2025.04.012

RECOMMENDED

Pulmonary Fibrosis

Clinical features associated with self-reported food insecurity in people with cystic fibrosis

★ 1 Recommended by Dr Martin Frey, Faculty Member

J Cyst Fibros

Boas H, Hsu JY, Koshy A, Seyoum S, Regenstein M, Hong G, Dieni O, Willis A, Ren CL

doi: 10.1016/j.jcf.2024.12.005

COMMENTED

Sleep Apnea

Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 0 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Benjafield AV, Pepin JL, Cistulli PA, Wimms A, Lavergne F, Sert Kuniyoshi FH, Munson SH, Schuler B, Reddy Badikol S, Wolfe KC, Willes L, Kelly C, Kendzerska T, Johnson DA, Heinzer R, Lee CH, Malhotra A, medXcloud Group

doi: 10.1016/S2213-2600(25)00002-5

RECOMMENDED

Pulmonary FibrosisPneumonia

Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution

doi: 10.1016/j.rmed.2025.108087

Lung Cancer

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

Nat Commun

Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, Wang S, Shen Z, Yu H, Yang Y, Zhou Y, Liu X, Song N, Zhu Y, Zhao D, Jiang G, Duan L, He W, Xie D, Dai J, Zhang L, Zhang P

doi: 10.1038/s41467-025-57184-z

Pulmonary FibrosisRespiratory Tract Infection

Real -World impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor

Respir Med

Holtzlander M, Lind M, Eisner M, Gushue C, Palacios S, Kotha K, Imran S, McCoy K, Sheikh S

doi: 10.1016/j.rmed.2025.108274

RECOMMENDED

Pulmonary Fibrosis

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data

★ 1 Recommended by Dr Martin Frey, Faculty Member

Sci Rep

Imrei M, Kéri AF, Gács É, Gönczi I, Meláth M, Kosaras É, Demeter B, Péterfia C, Vass K, Székely G, Ocskay K, Párniczky A

doi: 10.1038/s41598-025-86010-1

Related content

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Clinical features associated with self-reported food insecurity in people with cystic fibrosis

Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies

Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial

Real -World impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data